Specific Residues of RUNX2 Are Obligatory for Formation of BMP2-Induced RUNX2-SMAD Complex to Promote Osteoblast Differentiation

Amjad Javed^{a,c} Faiza Afzal^a Jong-Sup Bae^a Soraya Gutierrez^b Kaleem Zaidi^a
Jitesh Pratap^a Andre J. van Wijnen^a Janet L. Stein^a Gary S. Stein^a
Jane B. Lian^a

^aDepartment of Cell Biology and Cancer Center, University of Massachusetts Medical School, Worcester, Mass., USA;

^bDepartamento Biología Molecular, Universidad de Concepción, Concepción, Chile; ^cInstitute of Oral Health Research, School of Dentistry, University of Alabama at Birmingham, Birmingham, Ala., USA

Key Words

RUNX2 • Transcriptional regulation • SMAD coregulatory proteins • BMP2 osteogenic signaling

Abstract

BMP2 signaling and RUNX2 regulatory pathways converge for transcriptional control of bone formation in vivo. SMAD proteins are recruited to RUNX2 regulatory complexes via an overlapping nuclear matrix targeting signal/Smad interacting domain sequence (391–432) in Runx2. To establish the contribution of RUNX2-SMAD interaction to osteoblastogenesis, we characterized a number of point mutants. Only a triple mutation of amino acids 426–428 (HTY-AAA) results in loss of RUNX2 interactions with either BMP2- or TGF- β -responsive SMADs and fails to integrate the BMP2/TGF- β signal on target gene promoters. In a *Runx2* null cell reconstitution assay, the HTY mutant did not activate the program of osteoblast differentiation (alkaline phosphatase, collagen type 1, osteopontin, bone sialoprotein and osteocalcin) in response to BMP2 signaling. Thus, subnuclear targeting function and formation of a RUNX2-SMAD osteogenic complex are functionally inseparable. Taken together, these studies provide direct evidence that RUNX2 is essential for execution and completion of BMP2 signaling for osteoblast differentiation.

Copyright © 2008 S. Karger AG, Basel

Introduction

Transduction of the BMP and TGF- β signals results in the activation of target transcription factors, which is essential for differentiation and in vivo bone formation. SMAD proteins function as transducers of BMP/TGF- β signal in a variety of cell types [Xu and Massagué, 2004; Massagué et al., 2005]. There is mounting evidence that BMP signaling promotes multiple phenotypes through interaction of SMADs with other master transcription factors [Massagué et al., 2005]. The runt-related factor RUNX2 (Cbfa1/AML3) is critical for osteogenic lineage commitment and formation of the skeleton. Targeted disruption of *Runx2* in mice results in the maturational ar-

Abbreviations used in this paper

ALP	alkaline phosphatase
BMP	bone morphogenetic protein
FBS	fetal bovine serum
MEM	modified Eagle's medium
MOI	multiplicity of infections
NMTS	nuclear matrix targeting signal
SMID	Smad interacting domain
TGF- β	transforming growth factor- β
WT	wild type

rest of osteoblasts and a complete lack of mineralized bone [Komori et al., 1997; Otto et al., 1997; Choi et al., 2001]. RUNX protein provides a platform for assembly of a multicomponent regulatory complex that controls both activation and repression of genes during cell fate determination and differentiation [Javed et al., 1999, 2001; Gutierrez et al., 2002; Young et al., 2007]. The carboxy terminus of RUNX2 mediates interactions with a number of coregulatory proteins including SMADs [Zhang et al., 2000]. RUNX2-SMAD interaction is confined to a 41-amino acid Smad interacting domain (SMID) that overlaps with the nuclear matrix targeting signal (NMTS) [Afzal et al., 2005]. SMID suffices as an autonomous module that is both necessary and sufficient for interaction with SMADs. MAPK-mediated posttranslational modification of RUNX2 is an important component of the RUNX2-SMAD regulatory complex [Afzal et al., 2005].

The precise contact points for the RUNX2/SMAD physical association are yet to be established. Here we characterize a RUNX2 mutant that controls both formation of the RUNX2-SMAD complex and functional incorporation of the BMP2 osteogenic signal.

Materials and Methods

Cell Cultures

HeLa cells were cultured and maintained as previously described [Afzal et al., 2005]. Detailed description and morphological characteristics of the established *Runx2* null cell line from calvarial tissue of 17.5-day-old *Runx2* null mouse embryos was reported previously [Bae et al., 2006]. Cells were maintained in α -MEM supplemented with 10% FBS and penicillin/streptomycin (100 μ g/ml) at 37°C in a humidified atmosphere of 5% CO₂ in air.

Plasmids and Adenoviral Constructs

The BMP2- and TGF- β -responsive flag-tagged receptor SMAD (Smad2 and 3) constructs and the 6xRunx-luciferase plasmid were reported previously [Afzal et al., 2005]. Expression constructs of hemagglutinin-tagged RUNX2, deletion Δ 391, H426A, T427A, Y428A and HTY were described earlier [Afzal et al., 2005; Javed et al., 2005; Zaidi et al., 2006; Javed et al., 2008]. Wild type (WT), point and deletion mutants of *Runx2* adenoviruses were described previously [Afzal et al., 2005; Javed et al., 2008]. The following MOI were used for various *Runx2* adenoviruses to maintain an equal level of expression and low cytotoxicity in *Runx2* null cells: WT, 50; HTY, 60; Y428A, 70; Δ 391, 37.

Transient Transfection, Immunoprecipitation and Luciferase Assays

All transient transfections were performed using Superfect transfection reagent. For promoter reporter assays, HeLa cells were transfected with 0.5 μ g of *Runx2*, receptor *Smad* expression

vectors and TBRE-luciferase reporter. Transfected cells were cultured for an additional 18 h in the presence or absence of 100 ng/ml of BMP2 or TGF- β (5 ng/ml). Cells were lysed and luciferase activity was determined. Coimmunoprecipitations were performed as previously described. Western blots were probed with RUNX2 and flag antibodies, visualized with appropriate horseradish peroxidase-conjugated secondary antibody and chemiluminescence as described earlier [Javed et al., 2008].

Reconstitution Assays

Runx2 null cell cultures at 70% confluence were infected with the *Runx2* (WT, Y428A, HTY, Δ 391) or β -galactosidase adenovirus in serum-free MEM medium. After 90 min, cells were washed in α -MEM without serum followed by addition of complete α -MEM. Cells were cultured in the presence or absence of BMP2 (100 ng/ml) for an additional 12 days. Two days after infection, cells were fed with osteogenic media every other day and subsequently harvested at indicated days for RNA or alkaline phosphatase (ALP) histology as described previously [Javed et al., 2008].

Results and Discussion

RUNX2-SMAD Interaction Requires Specific Residues within the SMID/NMTS

We previously documented that the SMID in RUNX2 overlaps the well-characterized NMTS, which is required for organization of RUNX2 coregulatory protein complexes in unique subnuclear foci [Javed et al., 2000; Choi et al., 2001; Afzal et al., 2005]. From X-ray crystallography studies, this domain from 391 to 432 amino acids is structurally characterized by loop-turn-loop configuration [Tang et al., 1999]. The FTY and HTY residues form the tips of the interacting surfaces of loops 1 and 2, respectively, and are conserved among other family members and species (fig. 1a; data not shown). These amino acids along with residues in both the N- and C-terminal end of the SMID of RUNX2 were mutated to find the minimal requirements for interaction with SMAD proteins. Coimmunoprecipitation studies showed no changes in SMAD1 interaction with the triple mutations of FTY residues in loop 1, while the HTY mutation in loop 2 resulted in complete loss of interaction similar to the Δ 391 mutant which lacks SMID containing C terminus of *Runx2* (fig. 1b) [Javed et al., 2008]. Expression levels of SMAD1 and mutant RUNX2 proteins are shown in input samples (fig. 1b). Thus, the HTY motif in loop 2 of SMID is required for formation of the RUNX2-SMAD complex.

To further establish if the HTY residues represent the minimal contact point or if there are crucial amino acids within this motif for SMAD interaction, each of 3 residues of the HTY motif were mutated individually or in pairs. These results are summarized in figure 1. Loss of

Fig. 1. Three residues in the SMID of RUNX2 are required for formation of the RUNX2-SMAD complex. **a** Schematic illustration of various conserved region and C-terminal deletion as well as SMID mutant RUNX2 protein. QA = Polyglutamic acid and alanine stretch; RHD = DNA-binding runt homology domain; NLS = nuclear localization signal. SMID resides between amino acids 391 and 432. BMP2- or TGF- β -responsive SMAD (Smad1, 2 and 3) interactions with key RUNX2 point mutants determined

by coimmunoprecipitation studies are indicated. **b** HeLa cells were cotransfected with 5 μ g of *Smad1* and indicated *Runx2* expression vectors and cultured in the presence of 100 ng/ml of BMP2. Only mutation of all 3 amino acids resulted in loss of RUNX2-SMAD interaction. Lower panels show expression of RUNX2 and SMAD proteins in the input sample. IP = Immunoprecipitation; WB = Western blotting.

Fig. 2. Loss of osteogenic differentiation and BMP signal integration by HTY mutant RUNX2 protein. **a** Each TBRE element contains a Smad and an overlapping Runx DNA-binding motif. Cells were cotransfected as described and treated with 100 ng BMP2 and luciferase activity was determined. **b** Commitment of recon-

stituted *Runx2* null cells to osteoblast lineages was tested by ALP expression. Adenovirus-infected cells were cultured in the presence of BMP2 and relative expression levels of ALP marker gene were monitored by real-time RT-PCR analysis.

the RUNX2-SMAD interaction is observed only when all 3 amino acids (HTY) are mutated together or SMAD is deleted. We further found >70% loss of in situ colocalization of HTY mutant and SMAD (data not shown) [Javed et al., 2008]. Thus, the HTY mutation disrupts both biochemical and in situ association with receptor SMADs. These findings establish the HTY motif as a minimal contact point that is required for formation of the RUNX2-SMAD complex in response to BMP/TGF- β signaling.

Disruption of the RUNX2-SMAD Complex Impairs Integration of the BMP/TGF- β Signal Required for Commitment and Progression of Osteoblast Differentiation

We assessed the functional consequences of the disruption of the RUNX2-SMAD interaction by several criteria. RUNX2 transcriptional activation function was examined using a promoter that contains *cis*-elements for both Runx and Smad (3X-TBRE-Luc). BMP2 treatment resulted in 3-fold stimulation by WT but not with the HTY mutant (fig. 2a). HTY mutation does not change DNA binding (data not shown) [Javed et al., 2008], but selectively blocks integration of the BMP/TGF- β regulatory signal for promoter activity. To address if osteoblast differentiation is critically dependent on the RUNX2-SMAD molecular complex, we used a biological assay of reconstituted *Runx2* null cells. In the absence of RUNX2,

the null cells cannot be induced to the osteoblast lineage by BMP2 stimulation. Reintroduction of WT or Y428A RUNX2 restored the osteoblast phenotype with a progressive increase in ALP mRNA, which was further enhanced upon BMP2 stimulation (fig. 2b). In contrast, cells reconstituted with either HTY or Δ 391 RUNX2 mutant did not show any ALP expression in the absence or presence of BMP2. Expression of other osteogenic marker genes (collagen type 1, osteopontin, bone sialoprotein and osteocalcin) in response to BMP2 was similarly lost (data not shown) [Javed et al., JBC 2008]. These data demonstrate that loss of RUNX2-SMAD interaction impairs capacity of BMP2 to promote osteogenic differentiation.

In summary, these findings suggest that formation of the RUNX2-SMAD regulatory complex is obligatory for activation of a gene network that drives osteoblast differentiation. Furthermore, our results establish RUNX2 as a molecular endpoint that is required for execution and completion of TGF- β /BMP2 signaling in osteoblasts.

Acknowledgements

NIH sponsor contract grant numbers: AR39588, AG030228, DE12528. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.

References

- Afzal, F., J. Pratap, K. Ito, Y. Ito, J.L. Stein, A.J. van Wijnen, G.S. Stein, J.B. Lian, A. Javed (2005) Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription. *J Cell Physiol* 204: 63–72.
- Bae, J.S., S. Gutierrez, R. Narla, J. Pratap, R. Devados, A.J. van Wijnen, J.L. Stein, G.S. Stein, J.B. Lian, A. Javed (2007) Reconstitution of Runx2/Cbfa1-null cells identifies a requirement for BMP2 signaling through a Runx2 functional domain during osteoblast differentiation. *J Cell Biochem* 100: 434–449.
- Choi, J.-Y., J. Pratap, A. Javed, S.K. Zaidi, L. Xing, E. Balint, S. Dalamangas, B. Boyce, A.J. van Wijnen, J.B. Lian, J.L. Stein, S.N. Jones, G.S. Stein (2001) Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development. *Proc Natl Acad Sci USA* 98: 8650–8655.
- Gutierrez, S., A. Javed, D.K. Tennant, M. van Rees, M. Montecino, G.S. Stein, J.L. Stein, J.B. Lian (2002) CCAAT/enhancer-binding proteins (C/EBP) β and δ activate osteocalcin gene transcription and synergize with Runx2 at the C/EBP element to regulate bone-specific expression. *J Biol Chem* 277: 1316–1323.
- Javed, A., B. Guo, S. Hiebert, J.Y. Choi, J. Green, S.C. Zhao, M.A. Osborne, S. Stifani, J.L. Stein, J.B. Lian, A.J. van Wijnen, G.S. Stein (2000) Groucho/TLE/R-esp proteins associate with the nuclear matrix and repress RUNX (CBF α /AML/PEBP2 α) dependent activation of tissue-specific gene transcription. *J Cell Sci* 113: 2221–2231.
- Javed, A., G.L. Barnes, J. Pratap, T. Antkowiak, L.C. Gerstenfeld, A.J. van Wijnen, J.L. Stein, J.B. Lian, G.S. Stein (2005) Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. *Proc Natl Acad Sci USA* 102: 1454–1459.
- Javed, A., J.S. Bae, F. Afzal, S. Gutierrez, J. Pratap, S.K. Zaidi, Y. Lou, A.J. van Wijnen, J.L. Stein, G.S. Stein, J.B. Lian (2008) Structural coupling of Smad and Runx2 for execution of the BMP2 osteogenic signal. *J Biol Chem* 283: 8412–8422.
- Javed, A., S. Gutierrez, M. Montecino, A.J. van Wijnen, J.L. Stein, G.S. Stein, J.B. Lian (1999) Multiple Cbfa/AML sites in the rat osteocalcin promoter are required for basal and vitamin D-responsive transcription and contribute to chromatin organization. *Mol Cell Biol* 19: 7491–7500.
- Komori, T., H. Yagi, S. Nomura, A. Yamaguchi, K. Sasaki, K. Deguchi, Y. Shimizu, R.T. Bronson, Y.-H. Gao, M. Inada, M. Sato, R. Okamoto, Y. Kitamura, S. Yoshiki, T. Kishimoto (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell* 89: 755–764.
- Massague, J., J. Seoane, D. Wotton (2005) Smad transcription factors. *Genes Dev* 19: 2783–2810.

- Otto, F., A.P. Thornell, T. Crompton, A. Denzel, K.C. Gilmour, I.R. Rosewell, G.W. Stamp, R.S. Beddington, S. Mundlos, B.R. Olsen, P. B. Selby, M.J. Owen (1997) *Cbfa1*, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. *Cell* 89: 765–771.
- Tang, L., B. Guo, A. Javed, J.Y. Choi, S. Hiebert, J.B. Lian, A.J. van Wijnen, J.L. Stein, G.S. Stein, G.W. Zhou (1999) Crystal structure of the nuclear matrix targeting signal of the transcription factor acute myelogenous leukemia-1/polyoma enhancer-binding protein 2 α B/core binding factor α 2. *J Biol Chem* 274: 33580–33586.
- Xu, L., J. Massague (2004) Nucleocytoplasmic shuttling of signal transducers. *Nat Rev Mol Cell Biol* 5: 209–219.
- Young, D.W., M.Q. Hassan, X.Q. Yang, M. Galindo, A. Javed, S.K. Zaidi, P. Furcinitti, D. Lapointe, M. Montecino, J.B. Lian, J.L. Stein, A.J. van Wijnen, G.S. Stein (2007) Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2. *Proc Natl Acad Sci USA* 104: 3189–3194.
- Zaidi, S.K., A. Javed, J. Pratap, T.M. Schroeder, J. Westendorf, J.B. Lian, A.J. van Wijnen, G.S. Stein, J.L. Stein (2006) Alterations in intranuclear localization of Runx2 affect biological activity. *J Cell Physiol* 209: 935–942.
- Zhang, Y.W., N. Yasui, K. Ito, G. Huang, M. Fujii, J. Hanai, H. Nogami, T. Ochi, K. Miyazono, Y. Ito (2000) A RUNX2/PEBP2 α A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. *Proc Natl Acad Sci USA* 97: 10549–10554.